X

ASH 2021: Updates in MCL

ASH 2021: Updates in MCL

Study Reaffirms the Use of Cytarabine in Younger Patients With Mantle Cell Lymphoma

Long-term follow up of a phase 3 European MCL Network trial confirmed the previous observation of significantly prolonged time to treatment failure and longer OS with the addition...

Cancer Therapy Advisor
12/12/2021
Early Relapse Identifies MCL Patients With Inferior Survival After Intensive or Less Intensive Frontline Therapy

Investigators evaluated the prognostic significance of time to progression of disease in a large multiinstitutional MCL cohort including patients treated with either intensive or...

Blood Advances
12/07/2021
Single-Cell Sequencing Demonstrates Complex Resistance Landscape in CLL and MCL Treated with BTK and BCL2 Inhibitors

Taken together, these data reveal the significant clonal complexity of CLL and MCL progression on TAs at the nucleotide level and confirm the presence of multiple, clonally independent...

Blood Advances
12/03/2021

First-Line Ibrutinib/Rituximab in Patients With Mantle Cell Lymphoma Aged 65 and Older

In a single-institution phase II trial, chemo-free treatment with the combination of ibrutinib and rituximab produced high overall and complete response rates in patients with previously untreated

The ASCO Post
12/02/2021
ASH 2021 | Ascentage Pharma to Release Latest Data from Two Studies of Its Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a Chinese Study Demonstrating Complete Response

SUZHOU, China, and ROCKVILLE, MD., Nov. 4, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts on six studies of the company's three drug candidates (olverembatinib [HQP1351], lisaftoclax [APG-2575], and pelcitoclax [APG-1252]) have been selected for poster presentations and one oral presentation at the 63rd ASH Annual Meeting.

12/04/2021
Pirtobrutinib Shows Promising Efficacy in Heavily Pretreated MCL

Updated results from the BRUIN study demonstrated that pirtobrutinib has promising efficacy in heavily pretreated, poor-prognosis patients with MCL following multiple prior lines of therapy...

Oncology Learning Network
12/06/2021
Parsaclisib Monotherapy Well Tolerated in Patients With R/R MCL

Parsaclisib monotherapy showed rapid and durable response, an acceptable safety profile, and was generally well tolerated in BTK inhibitor-naïve patients with R/R MCL.

Oncology Learning Network
12/01/2021
Macrophage Counts in Tumor Microenvironment May Predict Prognosis for Mantle Cell Lymphoma

Lymphoma-associated macrophages may affect the prognosis of patients with mantle cell lymphoma, according to research published in Frontiers in Oncology.

Hematology Advisor
11/08/2021

source list reference

rgb(171, 222, 222)
#7d60d9
rgb(219, 18, 118)
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
rgb (247, 7, 79)
#352625
#4d4537
rgb(14, 133, 237)
rgb(80,199,199)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
#d2093c
#8e3f1c
rgb(242, 0, 137)
rgb (247, 7, 79)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
rgb (252, 186, 3)
#c61417
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb(11, 160, 224)
#cc529a
#c59445
rgb(245, 111, 66)
#c8cc0c
#bf6be3
rgb (245, 152, 2)
rgb(164, 116, 173)
rgb(219, 105, 96)
#e8085a
rgb(66, 135, 245)
#97d1a0
#74e391
#eb6342
#b61f77
rgb(169, 196, 201)
#a153ac
rgb(125, 127, 130)
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
rgb (191, 171, 145)
#89f67c
#49a21d
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rgb((217, 11, 193)
#2c990a
rbg(16, 162, 230)
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
rgb(107, 129, 201)
rgb (214, 104, 96)
rgb(224, 224, 4)
#a60538
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)
#49cde9
rgb(214, 139, 202)
#c20fce
rgb(80,199,199)
#d95d39
#eb5834